These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6601627)

  • 21. Impaired monocyte motility in sera from patients with systemic lupus erythematosus.
    Sturfelt G; Linder C; Sjöholm AG; Svensson B
    Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):151-8. PubMed ID: 6880748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum.
    Sobel AT; Bokisch VA; Müller-Eberhard HJ
    J Exp Med; 1975 Jul; 142(1):139-50. PubMed ID: 1097571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical aspects of the 125I-C1q binding assay for detecting immune complexes in tumor patients.
    Krieger G; Bause I; Kneba M; Kehl A; Nagel GA
    J Clin Lab Immunol; 1984 Jun; 14(2):87-92. PubMed ID: 6611419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of complement components C1q and C4 bound to circulating immune complexes in juvenile idiopathic arthritis: support for classical complement pathway activation.
    Gilliam BE; Reed MR; Chauhan AK; Dehlendorf AB; Moore TL
    Clin Exp Rheumatol; 2011; 29(6):1049-56. PubMed ID: 22153664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.
    WARD PA; COCHRANE CG; MUELLER-EBERHARD HJ
    J Exp Med; 1965 Aug; 122(2):327-46. PubMed ID: 14316948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of immune complex-mediated complement activation by autoantibodies (F-42) isolated from sera of patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Vanes LA
    Clin Exp Immunol; 1983 Sep; 53(3):541-6. PubMed ID: 6604604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of immune complexes by a microplate-adapted C1q-Protein A enzyme-linked-immunosorbent-assay (C1q-PA-ELISA).
    Bjerrum L; Glikmann G; Jensenius JC; Svehag SE
    J Clin Lab Immunol; 1983 Jan; 10(1):53-8. PubMed ID: 6338238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement.
    Beebe DP; Schreiber RD; Cooper NR
    J Immunol; 1983 Mar; 130(3):1317-22. PubMed ID: 6822737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement.
    Inada K
    Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies on the mechanism of haemopoietic stem cell (CFUs) mobilization. A role of the complement system.
    Wilschut IJ; Erkens-Versluis ME; Ploemacher RE; Benner R; Vos O
    Cell Tissue Kinet; 1979 May; 12(3):299-311. PubMed ID: 476778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of TNP-conjugated polyacrylamide beads in a C1q binding inhibition test for circulating immune complexes.
    Schmidt R; Walther S; Sodomann CP
    Immunobiology; 1982; 162(2):153-64. PubMed ID: 6981581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The complement subcomponent C1q mediates binding of immune complexes and aggregates to endothelial cells in vitro.
    Daha MR; Miltenburg AM; Hiemstra PS; Klar-Mohamad N; Van Es LA; Van Hinsbergh VW
    Eur J Immunol; 1988 May; 18(5):783-7. PubMed ID: 3259929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SLE like syndrome and functional deficiency of C1q in members of a large family.
    Hannema AJ; Kluin-Nelemans JC; Hack CE; Eerenberg-Belmer AJ; Mallée C; van Helden HP
    Clin Exp Immunol; 1984 Jan; 55(1):106-14. PubMed ID: 6319055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
    Parker CJ; White VF; Falk RJ
    Complement; 1986; 3(4):223-35. PubMed ID: 3643079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus.
    Butko P; Nicholson-Weller A; Wessels MR
    J Immunol; 1999 Sep; 163(5):2761-8. PubMed ID: 10453019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deficient classical complement pathway activity in newborn sera.
    Edwards MS; Buffone GJ; Fuselier PA; Weeks JL; Baker CJ
    Pediatr Res; 1983 Aug; 17(8):685-8. PubMed ID: 6412204
    [No Abstract]   [Full Text] [Related]  

  • 38. Activation of chemotactic factors in serum and wound fluid by dextranomer.
    Oredsson SU; Gottrup F; Beckmann A; Hohn DC
    Surgery; 1983 Sep; 94(3):453-7. PubMed ID: 6193593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of ionic strength, EDTA concentration, endogenous C1q and polyanions on the 125I-C1q-binding test.
    Hack CE; Huijbregts CC; Paardekooper J
    J Immunol Methods; 1984 Aug; 72(1):197-206. PubMed ID: 6205096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential precipitation of the Clq subcomponent of the first complement component (C1) by polyethylene glycol from normal human serum and sera of patients with collagen diseases.
    Van Dijk H; Van Voorst J; Jankowski IG; Imhof JW; Kerckhaert JA
    Clin Exp Immunol; 1984 Aug; 57(2):495-501. PubMed ID: 6432386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.